WO2006055603A3 - Injectable nanoparticulate olanzapine formulations - Google Patents

Injectable nanoparticulate olanzapine formulations Download PDF

Info

Publication number
WO2006055603A3
WO2006055603A3 PCT/US2005/041470 US2005041470W WO2006055603A3 WO 2006055603 A3 WO2006055603 A3 WO 2006055603A3 US 2005041470 W US2005041470 W US 2005041470W WO 2006055603 A3 WO2006055603 A3 WO 2006055603A3
Authority
WO
WIPO (PCT)
Prior art keywords
nanoparticulate olanzapine
injectable nanoparticulate
formulations
olanzapine formulations
injectable
Prior art date
Application number
PCT/US2005/041470
Other languages
French (fr)
Other versions
WO2006055603A2 (en
Inventor
Gary Liversidge
Scott Jenkins
Original Assignee
Elan Pharma Int Ltd
Gary Liversidge
Scott Jenkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36407708&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2006055603(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to AU2005307797A priority Critical patent/AU2005307797B2/en
Priority to BRPI0518187-9A priority patent/BRPI0518187A/en
Priority to EA200701065A priority patent/EA200701065A1/en
Priority to ES05851701.2T priority patent/ES2526092T3/en
Priority to KR1020077013288A priority patent/KR101290115B1/en
Application filed by Elan Pharma Int Ltd, Gary Liversidge, Scott Jenkins filed Critical Elan Pharma Int Ltd
Priority to EP05851701.2A priority patent/EP1827374B1/en
Priority to JP2007541454A priority patent/JP5324098B2/en
Priority to KR1020137005427A priority patent/KR20130030305A/en
Priority to CA2587710A priority patent/CA2587710C/en
Publication of WO2006055603A2 publication Critical patent/WO2006055603A2/en
Publication of WO2006055603A3 publication Critical patent/WO2006055603A3/en
Priority to IL183196A priority patent/IL183196A0/en
Priority to NO20073065A priority patent/NO342329B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/148—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/905—Specially adapted for travel through blood circulatory system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition

Abstract

Described are injectable formulations of nanoparticulate olanzapine that produce a prolonged duration of action upon administration, and methods of making and using such formulations. The injectable formulations comprise nanoparticulate olanzapine.
PCT/US2005/041470 2004-11-16 2005-11-16 Injectable nanoparticulate olanzapine formulations WO2006055603A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
CA2587710A CA2587710C (en) 2004-11-16 2005-11-16 Injectable nanoparticulate olanzapine formulations
JP2007541454A JP5324098B2 (en) 2004-11-16 2005-11-16 Injectable nanoparticulate olanzapine formulation
EA200701065A EA200701065A1 (en) 2004-11-16 2005-11-16 INJECTABLE COMPOSITIONS CONTAINING NANODISPERS Olanzapine
ES05851701.2T ES2526092T3 (en) 2004-11-16 2005-11-16 Olanzapine formulations in injectable nanoparticles
KR1020077013288A KR101290115B1 (en) 2004-11-16 2005-11-16 Injectable nanoparticulate olanzapine formulations
AU2005307797A AU2005307797B2 (en) 2004-11-16 2005-11-16 Injectable nanoparticulate olanzapine formulations
EP05851701.2A EP1827374B1 (en) 2004-11-16 2005-11-16 Injectable nanoparticulate olanzapine formulations
BRPI0518187-9A BRPI0518187A (en) 2004-11-16 2005-11-16 injectable nanoparticulate olanzapine formulations
KR1020137005427A KR20130030305A (en) 2004-11-16 2005-11-16 Injectable nanoparticulate olanzapine formulations
IL183196A IL183196A0 (en) 2004-11-16 2007-05-15 Injectable nanoparticulate olanzapine formulations
NO20073065A NO342329B1 (en) 2004-11-16 2007-06-15 Injectable nanoparticle-shaped olanzapine preparations, method of preparation and applications

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62874804P 2004-11-16 2004-11-16
US60/628,748 2004-11-16

Publications (2)

Publication Number Publication Date
WO2006055603A2 WO2006055603A2 (en) 2006-05-26
WO2006055603A3 true WO2006055603A3 (en) 2006-11-30

Family

ID=36407708

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/041470 WO2006055603A2 (en) 2004-11-16 2005-11-16 Injectable nanoparticulate olanzapine formulations

Country Status (14)

Country Link
US (2) US7910577B2 (en)
EP (2) EP1827374B1 (en)
JP (2) JP5324098B2 (en)
KR (2) KR20130030305A (en)
CN (1) CN101106972A (en)
AU (1) AU2005307797B2 (en)
BR (1) BRPI0518187A (en)
CA (1) CA2587710C (en)
EA (1) EA200701065A1 (en)
ES (1) ES2526092T3 (en)
IL (1) IL183196A0 (en)
NO (1) NO342329B1 (en)
WO (1) WO2006055603A2 (en)
ZA (1) ZA200703919B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8895546B2 (en) 2009-03-27 2014-11-25 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions
US9452131B2 (en) 2014-03-20 2016-09-27 Alkermes Pharma Ireland Limited Aripiprazole formulations having increased injection speeds

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
US20090155331A1 (en) * 2005-11-16 2009-06-18 Elan Pharma International Limited Injectable nanoparticulate olanzapine formulations
BRPI0712130A2 (en) * 2006-05-30 2012-01-17 Elan Pharma Int Ltd nanoparticulate posaconazole formulations
PT2040671T (en) * 2006-06-23 2018-03-14 Janssen Sciences Ireland Uc Aqueous suspensions of tmc278
US20080213374A1 (en) * 2006-07-10 2008-09-04 Elan Pharma International Limited Nanoparticulate sorafenib formulations
CL2008000746A1 (en) 2007-03-14 2008-09-22 Tibotec Pharm Ltd PHARMACEUTICAL COMPOSITION IN SOLUTION INCLUDING TMC278 AND A WATER SOLUBLE POLYMER; PREPARATION PROCESS OF SUCH COMPOSITION; AND USE OF A POWDER UNDERSTANDING TMC278 TO TREAT AIDS.
WO2008137960A1 (en) * 2007-05-07 2008-11-13 Questor Pharmaceuticals, Inc. Nasal administration of benzodiazepines
US20090258865A1 (en) 2008-03-28 2009-10-15 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions
JP6072539B2 (en) 2009-05-27 2017-02-01 アルカーメス ファーマ アイルランド リミテッド Reduction of flaky aggregation in nanoparticulate active agent compositions
US9012511B2 (en) 2010-05-19 2015-04-21 Alkermes Pharma Ireland Limited Nanoparticulate cinacalcet compositions
JP5893616B2 (en) 2010-10-18 2016-03-23 大日本住友製薬株式会社 Sustained release formulation for injection
PT3156056T (en) 2011-03-18 2024-03-04 Alkermes Pharma Ireland Ltd Pharmaceutical compositions comprising sorbitan esters
WO2013142198A1 (en) 2012-03-19 2013-09-26 Alkermes Pharma Ireland Limited Pharmaaceutical compositions comprising fatty acid esters
WO2013142202A1 (en) 2012-03-19 2013-09-26 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising glycerol esters
ES2950418T3 (en) * 2012-03-19 2023-10-09 Alkermes Pharma Ireland Ltd Pharmaceutical compositions comprising benzyl alcohol
CA2885196C (en) 2012-09-19 2021-06-22 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability
KR20150123838A (en) * 2013-03-04 2015-11-04 브이티브이 테라퓨틱스 엘엘씨 Stable glucokinase activator compositions
US10087443B2 (en) * 2013-10-28 2018-10-02 Icahn School Of Medicine At Mount Sinai Compositions and methods for modulating neuronal excitability and motor behavior
AR106085A1 (en) * 2015-09-21 2017-12-13 Teva Pharmaceuticals Int Gmbh OLANZAPINE FORMULATIONS OF SUSTAINED RELEASE
US20170196802A1 (en) * 2016-01-08 2017-07-13 Abon Pharmaceuticals, Llc Long Acting Injectable Formulations
CN106265541A (en) * 2016-08-31 2017-01-04 安徽省润生医药股份有限公司 A kind of injection olanzapine and preparation method thereof
WO2018111008A1 (en) 2016-12-14 2018-06-21 에스케이바이오팜 주식회사 Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder
US10646443B2 (en) 2017-03-20 2020-05-12 Teva Pharmaceuticals International Gmbh Sustained release olanzapine formulations
KR20200044016A (en) 2017-08-24 2020-04-28 노보 노르디스크 에이/에스 GLP-1 composition and use
US11273158B2 (en) 2018-03-05 2022-03-15 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
CN111569080A (en) * 2019-01-30 2020-08-25 鸡西代悦科技有限公司 Application of PLGA in preparation of SSRI antidepressant drug microspheres
JP7132441B2 (en) 2020-02-18 2022-09-06 ノヴォ ノルディスク アー／エス GLP-1 compositions and uses thereof
CN114177135B (en) * 2022-01-04 2022-11-15 朗天药业(湖北)有限公司 Peramivir pharmaceutical composition and preparation method thereof
WO2023139531A1 (en) * 2022-01-20 2023-07-27 Teva Pharmaceuticals International Gmbh Olanzapine, compositions thereof and methods of use thereof
CN115073492B (en) * 2022-08-22 2022-11-18 北京丹大生物技术有限公司 Olanzapine derivative antigen, olanzapine antibody and application thereof
CN115252622B (en) * 2022-09-26 2023-02-21 中日友好医院(中日友好临床医学研究所) Aldose reductase inhibitor and application thereof in preparation of medicine for treating lung cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0499299A2 (en) * 1991-01-25 1992-08-19 NanoSystems L.L.C. Surface modified drug nanoparticles
WO2000053164A1 (en) * 1999-03-08 2000-09-14 Elan Pharma International, Ltd. Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions
WO2004032980A1 (en) * 2002-10-04 2004-04-22 Elan Pharma International Limited Gamma irradiation of solid nanoparticulate active agents

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4330626A (en) * 1980-03-19 1982-05-18 The Enzyme Center, Inc. Method of preparing high-activity, low-bacteria, urease enzyme
US4826689A (en) * 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
US4783484A (en) * 1984-10-05 1988-11-08 University Of Rochester Particulate composition and use thereof as antimicrobial agent
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
FR2634376B1 (en) * 1988-07-21 1992-04-17 Farmalyoc NOVEL SOLID AND POROUS UNIT FORM COMPRISING MICROPARTICLES AND / OR NANOPARTICLES, AS WELL AS ITS PREPARATION
GB9009229D0 (en) * 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds
US5229382A (en) 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
AU642066B2 (en) * 1991-01-25 1993-10-07 Nanosystems L.L.C. X-ray contrast compositions useful in medical imaging
US5552160A (en) * 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
EP0593627A1 (en) * 1991-07-05 1994-04-27 The University Of Rochester Ultrasmall non-aggregated porous particles entrapping gas-bubbles
AU660852B2 (en) 1992-11-25 1995-07-06 Elan Pharma International Limited Method of grinding pharmaceutical substances
US5349957A (en) * 1992-12-02 1994-09-27 Sterling Winthrop Inc. Preparation and magnetic properties of very small magnetite-dextran particles
US5346702A (en) * 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5298262A (en) 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5302401A (en) * 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
US5340564A (en) * 1992-12-10 1994-08-23 Sterling Winthrop Inc. Formulations comprising olin 10-G to prevent particle aggregation and increase stability
US5336507A (en) * 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5429824A (en) * 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
US5352459A (en) * 1992-12-16 1994-10-04 Sterling Winthrop Inc. Use of purified surface modifiers to prevent particle aggregation during sterilization
US5401492A (en) * 1992-12-17 1995-03-28 Sterling Winthrop, Inc. Water insoluble non-magnetic manganese particles as magnetic resonance contract enhancement agents
US5326552A (en) * 1992-12-17 1994-07-05 Sterling Winthrop Inc. Formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight nonionic surfactants
US5264610A (en) * 1993-03-29 1993-11-23 Sterling Winthrop Inc. Iodinated aromatic propanedioates
US5716981A (en) * 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
US5362442A (en) * 1993-07-22 1994-11-08 2920913 Canada Inc. Method for sterilizing products with gamma radiation
TW384224B (en) 1994-05-25 2000-03-11 Nano Sys Llc Method of preparing submicron particles of a therapeutic or diagnostic agent
US5718388A (en) * 1994-05-25 1998-02-17 Eastman Kodak Continuous method of grinding pharmaceutical substances
US5525328A (en) * 1994-06-24 1996-06-11 Nanosystems L.L.C. Nanoparticulate diagnostic diatrizoxy ester X-ray contrast agents for blood pool and lymphatic system imaging
US5587143A (en) * 1994-06-28 1996-12-24 Nanosystems L.L.C. Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5628981A (en) * 1994-12-30 1997-05-13 Nano Systems L.L.C. Formulations of oral gastrointestinal diagnostic x-ray contrast agents and oral gastrointestinal therapeutic agents
US5466440A (en) * 1994-12-30 1995-11-14 Eastman Kodak Company Formulations of oral gastrointestinal diagnostic X-ray contrast agents in combination with pharmaceutically acceptable clays
US5585108A (en) * 1994-12-30 1996-12-17 Nanosystems L.L.C. Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays
US5662883A (en) 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5665331A (en) * 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5560932A (en) * 1995-01-10 1996-10-01 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents
US5569448A (en) * 1995-01-24 1996-10-29 Nano Systems L.L.C. Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5571536A (en) * 1995-02-06 1996-11-05 Nano Systems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5560931A (en) * 1995-02-14 1996-10-01 Nawosystems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5518738A (en) * 1995-02-09 1996-05-21 Nanosystem L.L.C. Nanoparticulate nsaid compositions
US5622938A (en) * 1995-02-09 1997-04-22 Nano Systems L.L.C. Sugar base surfactant for nanocrystals
US5534270A (en) * 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5593657A (en) * 1995-02-09 1997-01-14 Nanosystems L.L.C. Barium salt formulations stabilized by non-ionic and anionic stabilizers
US5500204A (en) * 1995-02-10 1996-03-19 Eastman Kodak Company Nanoparticulate diagnostic dimers as x-ray contrast agents for blood pool and lymphatic system imaging
US5591456A (en) * 1995-02-10 1997-01-07 Nanosystems L.L.C. Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5573783A (en) * 1995-02-13 1996-11-12 Nano Systems L.L.C. Redispersible nanoparticulate film matrices with protective overcoats
US5543133A (en) 1995-02-14 1996-08-06 Nanosystems L.L.C. Process of preparing x-ray contrast compositions containing nanoparticles
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5580579A (en) * 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
AU4990696A (en) * 1995-02-24 1996-09-11 Nanosystems L.L.C. Aerosols containing nanoparticle dispersions
US5747001A (en) * 1995-02-24 1998-05-05 Nanosystems, L.L.C. Aerosols containing beclomethazone nanoparticle dispersions
US5718919A (en) * 1995-02-24 1998-02-17 Nanosystems L.L.C. Nanoparticles containing the R(-)enantiomer of ibuprofen
US5565188A (en) * 1995-02-24 1996-10-15 Nanosystems L.L.C. Polyalkylene block copolymers as surface modifiers for nanoparticles
US5573749A (en) * 1995-03-09 1996-11-12 Nano Systems L.L.C. Nanoparticulate diagnostic mixed carboxylic anhydrides as X-ray contrast agents for blood pool and lymphatic system imaging
US5643552A (en) * 1995-03-09 1997-07-01 Nanosystems L.L.C. Nanoparticulate diagnostic mixed carbonic anhydrides as x-ray contrast agents for blood pool and lymphatic system imaging
US5472683A (en) * 1995-03-09 1995-12-05 Eastman Kodak Company Nanoparticulate diagnostic mixed carbamic anhydrides as X-ray contrast agents for blood pool and lymphatic system imaging
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
US5631250A (en) * 1995-03-24 1997-05-20 Eli Lilly And Company Process and solvate of 2-methyl-thieno-benzodiazepine
US5637584A (en) * 1995-03-24 1997-06-10 Eli Lilly And Company Solvate of olanzapine
US5521218A (en) * 1995-05-15 1996-05-28 Nanosystems L.L.C. Nanoparticulate iodipamide derivatives for use as x-ray contrast agents
US5573750A (en) * 1995-05-22 1996-11-12 Nanosystems L.L.C. Diagnostic imaging x-ray contrast agents
US5834025A (en) * 1995-09-29 1998-11-10 Nanosystems L.L.C. Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
TW491847B (en) * 1996-05-07 2002-06-21 Pfizer Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
UA57734C2 (en) * 1996-05-07 2003-07-15 Пфайзер Інк. Arylheterocyclic inclusion complexes
NZ332219A (en) * 1996-05-07 2005-02-25 Pfizer Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2(1H)-indol-2-one (ziprasidone), its preparation and its use as dopamine D2 antagonist
WO1998011893A1 (en) * 1996-09-23 1998-03-26 Eli Lilly And Company Olanzapine dihydrate d
ZA978515B (en) * 1996-09-23 1999-03-23 Lilly Co Eli Intermediates and process for preparing olanzapine
WO1998035666A1 (en) * 1997-02-13 1998-08-20 Nanosystems Llc Formulations of nanoparticle naproxen tablets
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
HUP0004534A3 (en) * 1997-09-30 2002-10-28 Lilly Co Eli Pharmaceutical formulation containing olanzapine
US6617321B2 (en) * 1997-09-30 2003-09-09 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
US6123923A (en) * 1997-12-18 2000-09-26 Imarx Pharmaceutical Corp. Optoacoustic contrast agents and methods for their use
IL127497A (en) * 1997-12-18 2002-07-25 Pfizer Prod Inc Pharmaceutical compositions containing piperazinyl-heterocyclic compounds for treating psychiatric disorders
US6066292A (en) * 1997-12-19 2000-05-23 Bayer Corporation Sterilization process for pharmaceutical suspensions
US6150366A (en) * 1998-06-15 2000-11-21 Pfizer Inc. Ziprasidone formulations
US6153225A (en) * 1998-08-13 2000-11-28 Elan Pharma International Limited Injectable formulations of nanoparticulate naproxen
US6165506A (en) * 1998-09-04 2000-12-26 Elan Pharma International Ltd. Solid dose form of nanoparticulate naproxen
AU759751B2 (en) * 1998-09-30 2003-05-01 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
JP4613275B2 (en) * 1998-11-02 2011-01-12 エラン ファーマ インターナショナル，リミティド Multiparticulate modified release composition
IT1303692B1 (en) * 1998-11-03 2001-02-23 Chiesi Farma Spa PROCEDURE FOR THE PREPARATION OF SUSPENSIONS OF PARTICLES OF DRUGS TO BE ADMINISTERED BY INHALATION.
US6375986B1 (en) * 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
US7521068B2 (en) * 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
US6428814B1 (en) * 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US6524528B1 (en) * 1999-03-02 2003-02-25 Suzanne C. Gottuso Method of sterilizing a tattooing solution through irradiation
US6270806B1 (en) * 1999-03-03 2001-08-07 Elan Pharma International Limited Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions
EP1185371B2 (en) * 1999-06-01 2008-11-12 Elan Pharma International Limited Small-scale mill and method thereof
US6656504B1 (en) * 1999-09-09 2003-12-02 Elan Pharma International Ltd. Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions
US7022698B2 (en) * 1999-12-28 2006-04-04 U & I Pharmaceuticals, Ltd. Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof
EP1136080A3 (en) * 2000-03-14 2002-06-05 Pfizer Products Inc. Use of o-vanillin and o-vanillin/trolox combinations
DE60140947D1 (en) * 2000-04-26 2010-02-11 Elan Pharma Int Ltd APPARATUS FOR SANITARY WET MASSING
US6316029B1 (en) * 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
US20040067936A1 (en) * 2000-08-31 2004-04-08 Reguri Buchi Reddy Process for preparation of hydrates of olanzapine and their conversion into crystalline forms of olanzapine
US6623761B2 (en) * 2000-12-22 2003-09-23 Hassan Emadeldin M. Method of making nanoparticles of substantially water insoluble materials
ES2309177T3 (en) * 2001-06-05 2008-12-16 Elan Pharma International Limited SYSTEM AND METHOD FOR MILLING MATERIALS.
US6908626B2 (en) * 2001-10-12 2005-06-21 Elan Pharma International Ltd. Compositions having a combination of immediate release and controlled release characteristics
WO2003043586A2 (en) * 2001-11-20 2003-05-30 Advanced Inhalation Research, Inc. Compositions for sustained action product delivery
AU2002367119A1 (en) * 2001-12-24 2003-07-15 Sun Pharmaceutical Industries Limited Crystalline form I of 2-methyl-4-(4-methyl-1-piperazinyl) 10H thieno [2,3-b][1,5]benzodiazepine
ATE464880T1 (en) * 2002-02-04 2010-05-15 Elan Pharma Int Ltd MEDICINAL NANOPARTICLES WITH LYSOZYME SURFACE STABILIZER
CA2492488A1 (en) * 2002-07-16 2004-01-22 Elan Pharma International, Ltd. Liquid dosage compositions of stable nanoparticulate active agents
EP1575962A1 (en) * 2002-12-24 2005-09-21 Teva Pharmaceutical Industries Limited Novel crystal forms of olanzapine, methods for their preparation and method for the preparation of known olanzapine crystal forms
HU226410B1 (en) * 2003-04-22 2008-11-28 Egis Gyogyszergyar Nyilvanosan Novel polymorphous forms of olanzapine hydrochlorides, process for producing them, use thereof and pharmaceutical compositions containing them
DK1667790T3 (en) * 2003-10-01 2007-09-24 Debio Rech Pharma Sa Particle Apparatus and Process
US7807828B2 (en) * 2005-08-11 2010-10-05 Hypnion, Inc. Olanzapine analogs and methods of use thereof
US7404228B2 (en) * 2005-09-16 2008-07-29 Hodges David L Paint roller frame

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0499299A2 (en) * 1991-01-25 1992-08-19 NanoSystems L.L.C. Surface modified drug nanoparticles
WO2000053164A1 (en) * 1999-03-08 2000-09-14 Elan Pharma International, Ltd. Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions
WO2004032980A1 (en) * 2002-10-04 2004-04-22 Elan Pharma International Limited Gamma irradiation of solid nanoparticulate active agents

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8895546B2 (en) 2009-03-27 2014-11-25 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions
US9452131B2 (en) 2014-03-20 2016-09-27 Alkermes Pharma Ireland Limited Aripiprazole formulations having increased injection speeds

Also Published As

Publication number Publication date
US7910577B2 (en) 2011-03-22
KR101290115B1 (en) 2013-07-29
KR20070094898A (en) 2007-09-27
EA200701065A1 (en) 2007-12-28
CA2587710C (en) 2014-10-21
WO2006055603A2 (en) 2006-05-26
JP5324098B2 (en) 2013-10-23
KR20130030305A (en) 2013-03-26
EP1827374B1 (en) 2014-11-05
AU2005307797A1 (en) 2006-05-26
ES2526092T3 (en) 2015-01-05
CA2587710A1 (en) 2006-05-26
ZA200703919B (en) 2008-09-25
EP1827374A2 (en) 2007-09-05
US20110195095A1 (en) 2011-08-11
IL183196A0 (en) 2007-08-19
BRPI0518187A (en) 2008-11-04
US20060154918A1 (en) 2006-07-13
NO342329B1 (en) 2018-05-07
CN101106972A (en) 2008-01-16
EP2623095A1 (en) 2013-08-07
NO20073065L (en) 2007-08-01
JP2008520581A (en) 2008-06-19
JP2013091649A (en) 2013-05-16
AU2005307797B2 (en) 2011-06-02

Similar Documents

Publication Publication Date Title
WO2006055603A3 (en) Injectable nanoparticulate olanzapine formulations
EP1740156B8 (en) Method for the production of an abuse-proof, solid form of administration
WO2007147010A3 (en) Implantable medical devices and methods for making the same
WO2006037810A3 (en) Protracted glp-1 compounds
WO2005027794A3 (en) Medical devices
WO2006037811A3 (en) Protracted exendin-4 compounds
WO2007064885A3 (en) Oral care compositions, methods, devices and systems
WO2007024705A3 (en) Method of treating depression using a tnf-alpha antibody
WO2006050477A3 (en) Anti-microbial compositions and methods of making and using the same
HRP20070374T3 (en) Formulations comprising ecteinascidin and a disaccharide
WO2004062577A3 (en) Two or more enteric materials to regulate drug release
WO2005110396A3 (en) Nitrated lipids and methods of making and using thereof
BRPI0513131A (en) sintered powdered confectionery
WO2006065360A3 (en) Medical devices formed with a sacrificial structure and processes of forming the same
MX2007007613A (en) Pharmaceutical formulations.
WO2005082020A8 (en) Flavivirus vaccines
IL184288A0 (en) 18-methyl-19-nor-17-pregn-4-en-21,17-carbolactones and pharmaceutical preparations comprising the same
WO2004001009A3 (en) Apo-2 ligand/trail variants and uses thereof
EP1731609A4 (en) Rad51 EXPRESSION INHIBITOR, DRUG CONTAINING THE INHIBITOR AS THE ACTIVE INGREDIENT AND UTILIZATION THEREOF
WO2006046114A3 (en) Osmotic dosage forms providing ascending drug release, and processes for their preparation
TW200621224A (en) Pharmaceutical composition
WO2007102946A3 (en) Crystalline polypeptides
WO2005077353A8 (en) Dichloroacetate in combination with an inotrope for cardioprotection
MXPA02001720A (en) Toy.
WO2005099822A3 (en) Reduction of drug / drug interactions with modafinil

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 183196

Country of ref document: IL

Ref document number: MX/a/2007/005885

Country of ref document: MX

Ref document number: 2007541454

Country of ref document: JP

Ref document number: 2587710

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 1820/KOLNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2005307797

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005851701

Country of ref document: EP

Ref document number: 1020077013288

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2005307797

Country of ref document: AU

Date of ref document: 20051116

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005307797

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200701065

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 200580046619.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 2005851701

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0518187

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 1020137005427

Country of ref document: KR